Comparative Pharmacology
Head-to-head clinical analysis: DIURIL versus DYAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIURIL versus DYAZIDE.
DIURIL vs DYAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium reabsorption in the distal convoluted tubule by blocking the sodium-chloride symporter, leading to increased excretion of sodium, chloride, and water.
Dyazide is a combination of hydrochlorothiazide, a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption; and triamterene, a potassium-sparing diuretic that blocks epithelial sodium channels in the collecting duct, reducing potassium excretion.
Adults: 500 mg to 1000 mg orally once or twice daily; maximum 2000 mg per day.
1-2 capsules orally once daily; each capsule contains hydrochlorothiazide 25 mg and triamterene 50 mg.
None Documented
None Documented
Terminal elimination half-life is 6-15 hours (mean 10 hours). In renal impairment, half-life can exceed 24 hours.
Triamterene: 1.5–2.5 hours; hydrochlorothiazide: 6–15 hours. Clinical dosing typically once daily.
Primarily renal (90-95% excreted unchanged via glomerular filtration and tubular secretion); minimal biliary/fecal (<5%).
Renal: triamterene ~80% (as metabolites and parent), hydrochlorothiazide >95% unchanged.
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic